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BACKGROUND: Approximately 25% of patients with pulmonary arterial hypertension (PAH) have been found to harbor rare 
mutations in disease-causing genes. To identify missing heritability in PAH, we integrated deep phenotyping with whole-
genome sequencing data using Bayesian statistics.
METHODS: We analyzed 13 037 participants enrolled in the NBR study (NIHR BioResource—Rare Diseases), of which 1148 
were recruited to the PAH domain. To test for genetic associations between genes and selected phenotypes of pulmonary 
hypertension, we used the Bayesian rare variant association method BeviMed.
RESULTS: Heterozygous, high impact, likely loss-of-function variants in the kinase insert domain receptor (KDR) gene 
were strongly associated with significantly reduced transfer coefficient for carbon monoxide (posterior probability=0.989) 
and older age at diagnosis (posterior probability=0.912). We also provide evidence for familial segregation of a rare 
nonsense KDR variant with these phenotypes. On computed tomographic imaging of the lungs, a range of parenchymal 
abnormalities were observed in the 5 patients harboring these predicted deleterious variants in KDR. Four additional PAH 
cases with rare likely loss-of-function variants in KDR were independently identified in the US PAH Biobank cohort with 
similar phenotypic characteristics.
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CONCLUSIONS: The Bayesian inference approach allowed us to independently validate KDR, which encodes for the VEGFR2 
(vascular endothelial growth factor receptor 2), as a novel PAH candidate gene. Furthermore, this approach specifically 
associated high impact likely loss-of-function variants in the genetically constrained gene with distinct phenotypes. These 
findings provide evidence for KDR being a clinically actionable PAH gene and further support the central role of the vascular 
endothelium in the pathobiology of PAH.
Key Words: computed tomography ◼ family history ◼ genetic association studies ◼ pulmonary hypertension  
◼ vascular endothelial growth factor receptor
P
ulmonary arterial hypertension (PAH) is character-
ized by pulmonary vascular constriction and oblit-
eration, causing elevation of pulmonary vascular 
resistance and ultimately, right ventricular failure. Molec-
ular mechanisms, such as aberrant angiogenesis,1 meta-
bolic reprogramming, and resistance to apoptosis,2 have 
been proposed to explain pulmonary vessel remodeling. 
A breakthrough in our understanding of the pathobiol-
ogy underlying PAH was the discovery of heterozygous 
germline mutations in the gene encoding the bone mor-
phogenetic protein receptor type 2 (BMPR2),3 responsi-
ble for over 70% of familial PAH cases and 15% to 20% 
of idiopathic PAH (IPAH) cases. A smaller proportion 
(up to 10%) of PAH cases are caused by mutations in 
activin-like kinase 1 (ACVRL1),4 endoglin (ENG),5 SMAD 
family member 9 (SMAD9),6 caveolin-1 (CAV1), involved 
in colocalization of BMP receptors,7 and the potassium 
channel KCNK3, responsible for membrane potential and 
vascular tone.8 We recently identified rare pathogenic 
variants in growth differentiation factor 2 (GDF2), which 
encodes BMP9 (bone morphogenetic protein 9), a major 
ligand of the BMPR2/ALK1 (activin receptor-like kinase 
1) receptor complex, as well as rare variants in ATPase 
13A3 (ATP13A3), aquaporin 1 (AQP1), and SRY-box 17 
(SOX17) and reported a list of additional putative genes 
potentially contributing to the pathobiology of PAH.9 
Together, the established genes explain ≈25% of cases 
with IPAH, allowing their reclassification as heritable 
PAH cases. To identify additional genes harboring poten-
tially causal rare variants in IPAH cases, we increased the 
cohort size10 and deployed a recently developed Bayes-
ian methodology11 that incorporates phenotypic data to 
increase the power to detect rare risk variants.
METHODS
Figure 1A provides an overview of the analysis strategy. The 
method details are described in the Data Supplement. The 
data of the NBR study (National Institute for Health Research 
BioResource—Rare Diseases) have been deposited in the 
European Genome-Phenome Archive.10 The data from the 
US PAH Biobank and the Columbia University Irving Medical 
Center are available via an application.12
Patients recruited to the NBR study provided informed 
consent for genetic analysis and clinical data capture (REC 
REF: 13/EE/0325); patients recruited by European col-
laborators consented to genetic testing and clinical data 
collection locally. Institutional review boards at Cincinnati 
Children’s Hospital Medical Center and Columbia University 
Irving Medical Center, and the US PAH Biobank Centers 
approved the validation cohort studies, and written informed 
consent was obtained at enrollment.
RESULTS
Characterization of Study Cohorts and Tag 
Definition
Whole-genome sequencing was performed in 13 037 
participants of the NBR study, of which 1148 were 
recruited to the PAH domain.10 The PAH domain included 
23 unaffected parents and 3 cases with an unknown 
phenotype, which were removed from the analysis 
(Figure 1B). Of the remaining 1122 participants, 972 
(86.6%) had a clinical diagnosis of IPAH, 73 (6.5%) 
of heritable PAH, and 20 (1.8%) were diagnosed with 
pulmonary veno-occlusive disease (PVOD)/pulmonary 
capillary hemangiomatosis (PCH). Diagnosis verifica-
tion revealed that 57 participants (5%) had a diagnosis 
other than IPAH, heritable PAH, or PVOD/PCH. These 
cases were subsequently relabelled and moved to the 
Nonstandard Abbreviations and Acronyms
BF Bayes factor
CT computerized tomography
ILD interstitial lung disease
IPAH  hereditary pulmonary arterial 
hypertension
KCO transfer coefficient for carbon monoxide
NBR NIHR BioResource—Rare Diseases
PAH pulmonary arterial hypertension
PCH pulmonary capillary hemangiomatosis
PH pulmonary hypertension
PP posterior probability
PVOD pulmonary veno-occlusive disease
VEGFR2  vascular endothelial growth factor 
receptor 2
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respective tag group for analysis (Table 1). The compre-
hensive clinical characterisation of the study cohort is 
shown in Table I in the Data Supplement. In summary, 
the median age at diagnosis was 49 [35;63] years with 
a female predominance of 68%. Europeans constituted 
84% of the study cohort. Overall survival in the studied 
population was 97% at one year, 91% at 3 years, and 
84% at 5 years. As expected, there was a significant 
difference in survival between prevalent and incident 
cases. In prevalent cases, survival at 1, 3, and 5 years 
was 98%, 93%, and 87%, whereas in incident cases it 
was 97%, 84%, and 72%, respectively. Median trans-
fer coefficient for carbon monoxide (KCO) in the entire 
studied population was 71 [52;86]% predicted. Cases 
in the lower tertile or below the KCO threshold of 50% 
predicted were more commonly male, older at diagnosis, 
had a current or past history of cigarette smoking and 
an increased number of cardiorespiratory comorbidities 
(Tables II, III, and IV in the Data Supplement). Survival in 
these groups was significantly worse than in those with 
preserved or mildly reduced KCO (Figure IA through ID 
in the Data Supplement). After adjusting for confound-
ing factors (age, sex, comorbidities, smoking status 
and whether the case was prevalent or incident), KCO 
remained an independent predictor of survival (Table V 
in the Data Supplement).
Figure 1. Design of the genetic association study.
A, Overview of the analytical approach. Using deep phenotyping, data tags were assigned to patients who shared phenotypic features. Rare 
sequence variants, called from whole-genome sequencing data, were filtered, and explained cases were labeled. BeviMed was applied to a 
set of unrelated individuals to estimate the posterior probability of gene-tag associations. B, Consort diagram summarizing the size of the study 
cohort. C, Schematic representation of the definition of cases, exemplified by the transfer coefficient for carbon monoxide (KCO) lower tertile 
tag. Cases were defined as individuals carrying a particular tag, whereas patients with missing information or those without a tag were removed 
from the gene-tag association testing. Individuals from non-pulmonary arterial hypertension (PAH) domains served as controls. CADD indicates 
combined annotation dependent depletion; and MAF, minor allele frequency.
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Age at diagnosis was calculated as age at the time of 
diagnostic right heart catheterisation and was available in 
all but 10 cases. Patients in the higher age tertile showed 
more functional impairment despite milder hemodynam-
ics, lower forced expiratory volume in one second/forced 
vital capacity ratio, and KCO (% predicted), as well as 
mild emphysematous and fibrotic changes on computer-
ized tomography (CT scans; Figure IE and IF and Table 
VI in the Data Supplement).
Rare Variants in Previously Established Genes
We identified variants in previously established genes 
(namely, BMPR2, ACVRL1, ENG, SMAD1, SMAD4, 
SMAD9, KCNK3, TBX4, EIF2AK4, AQP1, ATP13A3, GDF2, 
SOX17) in 271 (24.2%) of the 1122 cases and inter-
preted them based on the American College of Medical 
Genetics and Genomics standards and guidelines.13 The 
majority of these variants have already been described in 
Gräf et al9 (Material in the Data Supplement).
Rare Variant Association Testing
We used Bayesian methodology to consolidate previ-
ously reported PAH genes and to discover novel geno-
type-phenotype associations. Of note, cases explained 
by rare deleterious variants in previously established 
genes were only included for the association testing 
Table 1. Definitions of Labels and the Number of Unrelated Cases and Controls in the Rare Variant 
Association Analysis With BeviMed
Tag Tag description Cases Controls
Excluded 
relatives
PH Individuals with mPAP >25 mm Hg 1112 9134 2786
PAH Patients with one of the following diagnoses: IPAH, HPAH, 
PVOD, PCH, APAH:CHD-PAH, APAH:CTD-PAH, APAH:HIV-
PAH, APAH:PH-PAH
1085 9134 2786
I/HPAH Patients with a clinical diagnosis of IPAH or HPAH 1036 9134 2786
IPAH Patients with a clinical diagnosis of IPAH 972 9134 2785
HPAH Patients with a clinical diagnosis of HPAH 67 9136 2779
PVOD/PCH Patients with a clinical diagnosis of PVOD/PCH 20 9136 2778
I/HPAH/PVOD/PCH Patients with one of the following diagnoses: IPAH, HPAH, 
PVOD, PCH
1056 9134 2786
FPAH Patients with one of the following diagnoses: IPAH, HPAH, 
PVOD, PCH and a positive family history
80 9136 2781
APAH Patients with one of the following diagnoses: APAH:CHD-
PAH, APAH:CTD-PAH, APAH:HIV-PAH, APAH:PH-PAH
29 9136 2778
APAH: CHD-PAH Patients with PAH associated with congenital heart disease 17 9136 2778
APAH: CTD-PAH Patients with PAH associated with connective tissue disease 10 9136 2778
APAH: PoPH Patients with PAH associated with portopulmonary hyperten-
sion
1 9136 2778
APAH: HIV-PAH Patients with PAH associated with HIV 1 9136 2778
PH-LHD Patients with pulmonary hypertension associated with left 
heart disease (group 2)
7 9136 2778
PH-LD Patients with pulmonary hypertension associated with lung 
disease (group 3)
8 9136 2778
CTEPH Chronic thromboembolic pulmonary hypertension (group 4) 6 9136 2778
PH-multifactorial Multifactorial pulmonary hypertension (group 5) 6 9136 2778
young age Lower age tertile (<40.8 y) 378 9136 2785
middle age Middle age tertile (40.8–58.6 y) 376 9134 2779
old age Higher age tertile (>58.6 y) 355 9136 2778
low KCO KCO <50% pred 152 9136 2778
KCO lower tertile KCO <60% pred 211 9136 2778
KCO middle tertile KCO 60%–80% pred 215 9136 2778
KCO higher tertile KCO >80% pred 215 9134 2779
See paragraph on number of PAH domain samples in the analysis in the Data Supplement for more details. APAH indicates associated 
pulmonary arterial hypertension; CHD, congenital heart disease; CTD, connective heart disease; CTEPH, chronic thromboembolic pulmo-
nary hypertension; FPAH, familial PAH; I/HPAH, idiopathic/hereditary pulmonary arterial hypertension; KCO, transfer coefficient for carbon 
monoxide; LD, lung disease; LHD, left heart disease; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PCH, 
pulmonary capillary hemangiomatosis; PH, pulmonary hypertension; and PVOD, pulmonary veno-occlusive disease.
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with the respective disease gene (Methods in the Data 
Supplement). This analysis identified 40 significant 
gene-tag associations with posterior probability (PP) 
above 0.75 (Table 2 and Figure 2A). BMPR2, TBX4, 
EIF2AK4, ACVRL1, and AQP1 showed the highest asso-
ciation (PP ≥0.99), but we also confirmed significant 
associations in the majority of other previously identi-
fied genes. Individuals with rare variants in BMPR2, 
TBX4 (high impact), EIF2AK4 (biallelic), and SOX17 
had a significantly younger age of disease onset (tag: 
young age). We also confirmed the association of rare 
variants in AQP1 with familial PAH (log [BF]=10.023, 
PP=0.958). The refined phenotype approach corrobo-
rated the association between high impact variants in 
BMPR2 and preserved KCO (KCO higher tertile, log 
[BF]=99.923, PP=1) together with an association of 
biallelic EIF2AK4 mutations with significantly reduced 
KCO (KCO <50% predicted, log [BF]=29.741, PP=1).
Under an autosomal dominant mode of inheritance, 
high impact variants in the kinase insert domain recep-
tor (KDR) were associated with a significantly reduced 
KCO (KCO lower tertile, log [BF]=11.362, PP=0.989) 
and older age at diagnosis (tag: old age, log [BF]=9.249, 
PP=0.912).
Rare High Impact Variants in the New PAH 
Candidate Gene KDR
We identified 5 ultrarare high impact variants in KDR in 
the study cohort. Ultrarare variants exist in the general 
population only at a frequency of <1 in 10 000 (0.01%). 
Four of these were in PAH cases: one frameshift variant 
in exon 3 of 30 (c.183del, p.Tryp61CysfsTer16), 2 non-
sense variants, one in exon 3 (c.183G>A, p.Trp61Ter) 
and one in exon 22 (c.3064C>T, p.Arg1022Ter), and 
one splice acceptor variant in intron 4 of 29 (c.490-
1G>A). In addition, one nonsense variant was identi-
fied in exon 27 (p.Glu1206Ter) in a non-PAH control 
subject (Table 3). This latter nonsense variant appears 
late in the amino acid sequence, in exon 27 of 30, and 
hence is likely to escape nonsense-mediated decay, 
but this remains to be studied functionally. All loss-of-
function variants were confirmed by Sanger sequenc-
ing (Figure 3 and Figure II in the Data Supplement). 
Furthermore, 13 PAH cases (1%) and 108 non-PAH 
controls (0.9%) harbored rare, predicted-deleterious 
KDR missense variants of moderate impact (Figure 3). 
The missense variant carriers, however, did not exhibit 
a reduced KCO or older age at diagnosis. Instead, 
these patients show the opposite trend in KCO (Fig-
ure 2B and 2C). Importantly, 7 of the 13 KDR missense 
variants seen in PAH cases were also detected in sev-
eral non-PAH controls and thus, are of unknown sig-
nificance. Furthermore, 3 of these missense variants 
co-occurred with a predicted-deleterious variant in an 
established PAH risk gene (2 patients carried also a 
variant in BMPR2 and one a variant in AQP1).
Clinical Characterization of KDR Mutation 
Carriers
Patients with high impact variants in KDR were older and 
exhibited significantly reduced KCO similar to biallelic 
EIF2AK4 mutation carriers and in contrast to KDR mis-
sense variant and BMPR2 mutation carriers (Figure 2B 
and 2C). Three of the 4 cases did not have a history of 
smoking. CT scans for all 4 patients showed a range of 
mild lung parenchymal changes (Figure 4). W000229 
had evidence of mild mainly subpleural interstitial 
lung disease (ILD), mild emphysema, and air trapping. 
W000274 had signs of ILD with traction bronchiectasis 
in the lower zones, mild air trapping, and mild diffuse 
ground-glass opacities and neovascularity. E001392 
showed mild centrilobular ground-glass opacities in 
addition to moderate pleural effusion and a trace of air 
trapping, but no ILD. In these cases, it seemed likely 
that the observed parenchymal changes contributed 
to the low KCO. In contrast, E003448 had a low KCO 
despite only a trace of central nonspecific ground-glass 
opacities on the CT images. Comparisons of CT find-
ings between patients harboring deleterious mutations 
in BMPR2, EIF2AK4, KDR, other PAH risk genes and 
patients without mutations are presented in Table VII 
in the Data Supplement. There were no differences in 
the frequency of comorbidities between patients har-
boring missense and loss-of-function variants in KDR 
although the frequency of systemic hypertension was 
high (44%; Table VIII in the Data Supplement). Survival 
analysis could not be conducted due to the small num-
ber of mutation carriers, as well as only 2 events occur-
ring in this group. Following the death of W000229, his 
daughter, aged 53, was diagnosed with PAH and had a 
reduced KCO at 40% predicted. On the CT scan, mild 
interstitial fibrosis was observed (Figure III in the Data 
Supplement). Sanger sequencing confirmed that father 
and daughter carried the same deleterious KDR non-
sense variant p.Trp61Ter (Figure 3B).
Additional KDR Cases in US PAH Cohorts
To seek further evidence for KDR as a new candidate 
gene for PAH, we analyzed subjects recruited to the US 
PAH Biobank12 and the Columbia University Irving Med-
ical Center14 to identify additional patients carrying 
predicted pathogenic rare variants. Four additional indi-
viduals harboring rare high impact KDR variants were 
identified. These comprised, 2 nonsense variants, one 
in exon 3 (c.303C>A, p.Tyr101Ter) and one in exon 22 
(c.3064C>T, p.Arg1022Ter) and 2 splice donor variants, 
one in intron 2 of 29 (c.161+1G>T) and one in intron 
5 (c.658+1G>A). Interestingly, the nonsense variant 
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p.Arg1022Ter appeared in both cohorts (Figure 3). 
Patient-level data for these individuals are summarized 
in Table 3. Three of the 4 patients were diagnosed with 
IPAH at 72, 65, and 42 years, respectively, whereas one 
patient was diagnosed at age 4 with PAH associated 
with double outlet right ventricle. The diffusing capacity 
Table 2. BeviMed Analysis Results
Gene Transcript Tag log (Bayes factor)
Posterior  
probability Consequence type
Mode of  
inheritance
BMPR2 ENST00000374580 I/HPAH 265.762 1.000 High Dominant
BMPR2 ENST00000374580 PAH 265.639 1.000 High Dominant
BMPR2 ENST00000374580 I/HPAH/PVOD/PCH 263.481 1.000 High Dominant
BMPR2 ENST00000374580 PH 262.625 1.000 High Dominant
BMPR2 ENST00000374580 Young age 149.576 1.000 Moderate and high Dominant
BMPR2 ENST00000374580 HPAH 149.091 1.000 Moderate and high Dominant
BMPR2 ENST00000374580 FPAH 147.822 1.000 Moderate and high Dominant
BMPR2 ENST00000374580 IPAH 144.582 1.000 High Dominant
BMPR2 ENST00000374580 KCO higher tertile 99.923 1.000 High Dominant
BMPR2 ENST00000374580 Middle age 63.119 1.000 Moderate and high Dominant
BMPR2 ENST00000374580 KCO middle tertile 52.706 1.000 Moderate and high Dominant
EIF2AK4 ENST00000263791 Low KCO 29.741 1.000 Moderate and high Recessive
EIF2AK4 ENST00000263791 KCO lower tertile 26.247 1.000 Moderate and high Recessive
TBX4 ENST00000240335 I/HPAH 23.783 1.000 High Dominant
TBX4 ENST00000240335 I/HPAH/PVOD/PCH 23.549 1.000 High Dominant
TBX4 ENST00000240335 PAH 23.141 1.000 High Dominant
TBX4 ENST00000240335 PH 22.877 1.000 High Dominant
EIF2AK4 ENST00000263791 Young age 20.547 1.000 Moderate and high Recessive
TBX4 ENST00000240335 IPAH 19.990 1.000 High Dominant
EIF2AK4 ENST00000263791 I/HPAH/PVOD/PCH 15.718 1.000 Moderate and high Recessive
ACVRL1 ENST00000388922 HPAH 15.501 1.000 Moderate and high Dominant
EIF2AK4 ENST00000263791 PAH 15.407 1.000 Moderate and high Recessive
EIF2AK4 ENST00000263791 PH 15.071 1.000 Moderate and high Recessive
EIF2AK4 ENST00000263791 PVOD/PCH 14.441 0.999 Moderate and high Recessive
AQP1 ENST00000311813 HPAH 12.075 0.994 Moderate Dominant
EIF2AK4 ENST00000263791 FPAH 11.858 0.993 High Recessive
TBX4 ENST00000240335 Young age 11.500 0.990 High Dominant
AQP1 ENST00000311813 I/HPAH 11.466 0.990 Moderate and high Dominant
KDR ENST00000263923 KCO lower tertile 11.362 0.989 High Dominant
AQP1 ENST00000311813 I/HPAH/PVOD/PCH 11.291 0.988 Moderate and high Dominant
AQP1 ENST00000311813 PAH 11.047 0.984 Moderate and high Dominant
AQP1 ENST00000311813 PH 10.791 0.980 Moderate and high Dominant
AQP1 ENST00000311813 FPAH 10.023 0.958 Moderate Dominant
KDR ENST00000263923 Old age 9.249 0.912 High Dominant
GDF2 ENST00000249598 I/HPAH 9.091 0.899 Moderate and high Dominant
BMPR2 ENST00000374580 Old age 8.913 0.881 High Dominant
GDF2 ENST00000249598 I/HPAH/PVOD/PCH 8.775 0.866 Moderate and high Dominant
SOX17 ENST00000297316 Young age 8.554 0.839 Moderate and high Dominant
GDF2 ENST00000249598 PAH 8.478 0.828 Moderate and high Dominant
ATP13A3 ENST00000439040 KCO higher tertile 8.035 0.755 High Dominant
Posterior probabilities and BF of gene-tag associations (prior probability π=0.001). The BF is the ratio between the probabilities of the data under H1 and 
under H0. The observed data are BF times more likely under H1 than under H0, and so the larger the BF, the stronger the support in the data for H1 compared 
with H0. The high category comprises only variants of high impact, including loss-of-function variants and large deletions; the moderate category contains variants 
of moderate impact, including missense variants or variants of consequence type non_coding_transcript_exon_variant; the combined category moderate and high 
includes both respective consequence types. BF indicates Bayes factors; FPAH, familial PAH; I/HPAH, idiopathic/hereditary pulmonary arterial hypertension; 
KCO, transfer coefficient for carbon monoxide; PAH, pulmonary arterial hypertension; PCH, pulmonary capillary hemangiomatosis; PH, pulmonary hypertension; 
and PVOD, pulmonary veno-occlusive disease.
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of carbon monoxide was available for one patient and 
was decreased at 35% predicted, with minor pleural 
scarring in the left upper lobe found on CT imaging. Two 
out of 4 patients (50%) harboring a high impact variant 
in KDR had been diagnosed with systemic hypertension.
DISCUSSION
One of the critical steps in identifying novel, causative 
genes in rare disorders is the discovery of genotype-phe-
notype associations to inform patient care and outcomes. 
A pragmatic focus on deeply phenotyped individuals and 
Figure 2. Rare variant association study results revealing established and novel genotype-phenotype links.
A, Figure showing phenotype tags on the x axis and corresponding posterior probability of genotype-phenotype association on the y axis, 
as calculated by BeviMed. The definitions of the tags are listed in Table 1. Shape and colour of points indicate the mode of inheritance and 
impact/consequence type of variants driving the association. Box-and-whisker plots showing the distribution of (B) the transfer coefficient for 
carbon monoxide (KCO) and (C) the age at diagnosis stratified by genotype across the pulmonary arterial hypertension (PAH) domain. The 
2-tailed Wilcoxon signed-rank test was used to determine differences in the medians of the distributions, which are indicated by the bars at the 
top of the figures providing the respective P values. ACVRL1 indicates activin-like kinase 1; AQP1, aquaporin 1; bial, biallelic; BMPR2, bone 
morphogenetic protein receptor type 2; EIF2AK4, eukaryotic translation initiation factor 2 alpha kinase 4; FPAH, familial PAH; GDF2, growth 
differentiation factor 2; I/HPAH, idiopathic/hereditary pulmonary arterial hypertension; lof, loss-of-function; mis, missense; PAH, pulmonary 
arterial hypertension; PH, pulmonary hypertension; PVOD/PCH, pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis; and 
TBX4, T-box transcription factor 4.
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Table 3. Gene Changes for Patients With IPAH Harboring Likely Loss-of-Function Variants in the KDR Gene
Cohort United Kingdom United States









Exon 3/30 3/30  22/30 3/30 2/30 3/30 5/30 22/30
HGVSc c.183G>A c.183G>A c.490-
1G>A
c.3064C>T c.183del c.161+1G>T c.303C>A c.658+1G>A c.3064C>T










Stop gained Frameshift variant Splice donor 
variant
Stop gained Stop gained Stop gained
Shared PAH (1) PAH (1) PAH (1) PAH (1) PAH (1) PAH (1) PAH (1) PAH (1) PAH (1)
gnomAD NA NA NA NA NA NA NA NA NA
CADD PHRED 
v1.3
38 38 26 37 35 26.4 38 24.3 37
GerpN 5.93 5.93 5.75 5.95 5.93 5.83 5.48 5.8 5.95
Ancestry European European European European European East-Asian European European European
Sex Male Female Female Male Female Female Male Female Female





Age at  
diagnosis, y
71 53 62 67 61 4 72 65 42
WHO FC 2 3 3 3 3 2 NA NA NA
6MWD, m 472 202 422 660 180 NA 380 NA 245
SpO
2
 pre, % 95 96 97 98 97 NA NA NA NA
SpO
2
 post, % 86 87 86 NA 91 NA NA NA NA
FEV
1
, % pred. 116 70 90 83 67.3 85% NA 77% NA
FVC, % pred. 115 76 94 91 72.8 92% NA 83% NA
TLC, % pred. NA 69 NA NA NA NA NA 65% NA
KCO, % pred. 44 40 46 46 55.2 NA NA 35%* NA
Smoking history Never Never Never Ex-smoker Never Never Never Ex-smoker Never
mRAP, mm Hg 5 13 8 8 3 NA 5 29 14
mPAP, mm Hg 62 45 57 41 44 NA 49 66 60
PAWP, mm Hg 4 5 15 12 9 NA 5 16 15
CO, L/min 3.6 3.3 4.58 5.97 5.23 NA 4.33 1.8 4.6
















sity, CAD, DM 
type 2, hypo-
thyroidism
Family history Yes, 
daughter
Yes, father No No No No No No No
Status Dead Alive Alive Alive Dead Alive Alive Alive Alive
None of the KDR variants have previously been reported in gnomAD, ExAC, or internal controls. HGVSc notations are based on transcript sequence 
ENST00000263923.4. HGVSp notations are based on the amino acid sequence ENSP00000263923.4. 6MWD indicates 6-minute walk distance; APAH-CHD, as-
sociated pulmonary arterial hypertension with congenital heart disease; ASD, atrial septal defect; CAD, coronary artery disease; CADD, combined annotation dependent 
depletion; CO, cardiac output; CUMC, Columbia University Irving Medical Center; DM, diabetes; FEV
1
, forced expiratory volume in 1 sec; FVC, forced vital capacity; GerpN, 
Conservation score of each nucleotide in multi-species alignment; gnomAD, The Genome Aggregation Database; HGVSc, HGVS notation of coding sequence; HGVSp, 
HGVS notation of protein sequence; HTN, systemic hypertension; IPAH, idiopathic pulmonary arterial hypertension; KCO, transfer factor coefficient for carbon monoxide; 
KDR, Kinase insert domain receptor; mPAP, mean pulmonary artery pressure; mPAWP, mean pulmonary artery wedge pressure; mRAP, mean right atrial pressure; OA, 
osteoarthritis; OSA, obstructive sleep apnea; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; SIFT, Sorting Intolerant From Tolerant prediction 
score; SpO
2
, arterial oxygen saturation; TLC, total lung capacity; and WHO FC, World Health Organization functional class.
*DLCO % predicted.
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smart experimental design provides additional leverage 
to identify novel risk variants.15 To deploy this approach in 
PAH, we brought together phenotypic and genetic data 
using Bayesian methodology.11 This Bayesian framework 
allows the inclusion of prior information regarding the 
hypothesis being tested in a flexible manner and com-
pares a range of possible genetic models in a single 
analysis. To generate case-control labels, we tagged PAH 
cases with diagnostic labels and stratified them by age 
at diagnosis and KCO. Analyses were then performed 
to identify associations between tags and ultrarare gene 
variants under dominant and recessive modes of inheri-
tance and different variant impact categories.
Our Bayesian methodology analysis provided strong 
statistical evidence of an association between ultrarare, 
high impact variants in KDR and PAH with significantly 
reduced KCO and older age at diagnosis under a domi-
nant mode of inheritance. Strikingly, likely loss-of-func-
tion variants in KDR exist in the general population with 
a frequency of only 4 to 7 per 100 000 (see Table 4). In 
Figure 3. Summary of rare single nucleotide variants (SNVs) and small insertions and deletions (indels) identified in the novel 
pulmonary arterial hypertension (PAH) candidate gene KDR (kinase insert domain receptor).
A, Only rare predicted deleterious variants in KDR are shown (minor allele frequency [MAF] <1/10 000 and combined annotation dependent 
depletion [CADD] ≥10). SNVs and indels are represented by colored lollipops on top of the protein sequence. The domain annotations were 
retrieved from Uniprot (accession number P35968). Lollipop colors indicate the consequence type, and sizes represent the variant frequency 
within a cohort. Missense variants that are predicted to be deleterious (Sorting Intolerant From Tolerant prediction score [SIFT]) and damaging 
(PolyPhen-2) are colored in red, otherwise in yellow (ie, SIFT and PolyPhen-2 disagree). High impact variants are labelled with the respective 
Human Genome Variation Society notation. The number of variants by predicted consequence type and cohort is provided in the table. B, 
Familial segregation of KDR nonsense variant c.183G>A (p.Trp61*) with PAH (ie, reduced KCO and late onset) from father (W000229) to 
daughter (W000229.d). Sanger sequencing results are shown in the chromatograms. NBR indicates NIHR BioResource—Rare Diseases; and 
USBB, US PAH Biobank.
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contrast, we identified 4 PAH cases in the NBR cohort 
which equates to almost 2 in 1000. Additionally, the sta-
tistical constraint metrics provided by Genome Aggrega-
tion Database16 strongly suggest that loss-of-function 
variants in KDR are not tolerated (pLI=1; o/e=0.15 
[0.09;0.25]). Besides the statistical evidence, we also 
identified one additional case with a family history, which 
together with a recently published case report of 2 fami-
lies in which loss-of-function variants in KDR segregated 
with PAH and significantly reduced KCO,17 amounts to 3 
reported familial cases with a distinct phenotype.
Vascular endothelial growth factor receptor 
2 (VEGFR2), which is encoded by KDR,18 binds VEGFA, 
a critical growth factor for physiological and pathologi-
cal angiogenesis in vascular endothelial cells. In mice, 
even though VegfA haploinsufficiency is embryoni-
cally lethal,19 heterozygosity of its receptor, Vegfr2, is 
compatible with life and unperturbed vascular develop-
ment.20 The role of VEGF signaling in the pathogen-
esis of PAH has been an area of intense interest since 
increased expression of VEGF, VEGFR1, and VEGFR2 
were reported in rat lung tissue in response to acute and 
chronic hypoxia.21 An increase in lung VEGF has also 
Figure 4. Chest computerized 
tomography (CT) scans of patients 
carrying high impact kinase insert 
domain receptor (KDR) mutations.
A, Axial image of CT pulmonary 
angiogram at the level of the right 
ventricle (RV) moderator band, showing 
flattening of interventricular septum, 
leftwards bowing of the interatrial septum 
and the enlargement of the right atrium 
(RA) and RV, indicative of RV strain; 
bilateral pleural effusion, larger on the 
right side. B, Axial image of a pulmonary 
CT angiogram demonstrating enlarged 
pulmonary artery and mild central lung 
ground-glass opacity (GGO). C, Axial 
high-resolution CT slice of the chest in 
the lung window showing a trace of non-
specific GGO with a central distribution. 
D, Coronal image showing the trace 
of central GGO and enlarged central 
pulmonary arteries. Axial high-resolution 
CT slice of the chest in the lung window 
showing apical subpleural fibrosis (E), 
and very minor subpleural fibrosis at the 
lung bases (F). Axial high-resolution CT 
slice of the chest in the lung window 
showing subpleural GGO at apical level 
(G), and mild GGO at mid-thoracic 
level (H). Patients: E001392 (A and B), 
E003448 (C and D), W000229 (E and 
F), W000274 (G and H).
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been reported in rats with pulmonary hypertension (PH) 
following monocrotaline exposure.22 In humans, VEGF-
A is highly expressed in plexiform lesions in patients 
with IPAH.23 In addition, inhibition of VEGF signaling by 
SU5416 (sugen) combined with chronic hypoxia trig-
gers severe angioproliferative PH.24 SU5416, a small-
molecule inhibitor of the tyrosine kinase segment of 
VEGF receptors, inhibits VEGFR1,25 and VEGFR226 
causing endothelial cell apoptosis, loss of lung capil-
laries, and emphysema.27 Further evidence supporting 
the role of VEGF inhibition in the pathobiology of PAH 
comes from reports of PH in patients treated with beva-
cizumab28 and the multi-tyrosine kinase inhibitors.29,30 
Mutations in KDR have also been linked to congenital 
heart diseases. Bleyl et al31 reported that KDR might 
be a candidate for familial total anomalous pulmonary 
venous return. In addition, haploinsufficiency at the KDR 
locus has also been associated with tetralogy of Fal-
lot.32 We identified one patient in the Columbia Univer-
sity Irving Medical Center cohort with PAH associated 
with congenital heart disease harboring a KDR likely 
protein-truncating splice donor variant (c.161+1G>T).
In the present study, we highlight that deep clinical 
phenotyping, in combination with genotype data, can 
improve the identification of novel disease risk genes 
and disease subtypes. KDR was already identified 
as a possible candidate gene, which did not achieve 
genome-wide significance, in our previous rare variant 
association study.9 In combination with deep phenotyp-
ing data, KDR reached in the present study a signifi-
cance level comparable to the most commonly affected 
genes in PAH. Reduced KCO, which reflects impairment 
of alveolar-capillary membrane function, has been noted 
in the analysis of early PAH registry data33 to be an 
independent predictor of survival. Decreased KCO was 
also found in patients with PVOD/PCH with or without 
biallelic EIF2AK4 mutations.34 Although some reduction 
in KCO is one of the typical features of pulmonary vas-
cular disease, patients with PVOD show the lowest KCO 
values when compared with IPAH or chronic thrombo-
embolic pulmonary hypertension. In contrast, KCO is rel-
atively preserved in BMPR2 mutation carriers.35 Strong 
association with survival and a link with other causative 
mutations makes the KCO phenotype particularly attrac-
tive for stratification in genetic studies.
As lung disease should always be taken under con-
sideration as a cause of low KCO, we applied the World 
Symposium on PH criteria36 to exclude lung disease as a 
cause of PH: total lung capacity ≥70% pred., forced vital 
capacity ≥70% pred., forced expiratory volume in one 
second ≥60% pred., and no severe fibrosis and emphy-
sema on chest CT. None of the cases carrying a high 
impact variant in KDR met these criteria, although 2 of 
the 4 patients did show evidence of early ILD. Another 
potential reason for low KCO in the PAH population is 
the diagnosis of PVOD/PCH.37,38 Careful analysis of CT 
scans and clinical data did not reveal convincing evidence 
for this diagnosis in KDR mutation carriers. Cigarette 
smoking is a well-known factor leading to the decrease 
of KCO. Only one of the 4 KDR high impact variant car-
riers had a significant 15 pack-years smoking history, 
but with no signs of emphysema on CT. These findings 
suggest that loss-of-function variants in KDR are asso-
ciated with a form of PAH characterized by a range of 
lung parenchymal abnormalities, including small airways 
disease, emphysema and ILD, as 2 of the 4 patients har-
boring a high impact variant in KDR had mild fibrotic lung 
changes. Notably, patients with mutations in other PAH 
risk genes, or those without the identified genetic muta-
tion, showed <10% incidence of fibrotic changes on CT 
imaging. Further larger studies are needed to determine 
the full range of lung parenchymal abnormalities in PAH 
cases with deleterious variants in KDR.
In this study, we have assumed that PAH is a mono-
genic condition, which is caused by either deleterious 
heterozygous or biallelic variants in a single gene. This 
assumption, although widely supported by the literature, 
may not be entirely accurate. Alternatively, some cases of 
PAH might represent an oligogenic inheritance involving 
2 or more genes. Although not statistically explored in 
the current analysis, we found a total of 22 PAH cases 
carrying deleterious variants in more than one PAH gene. 
These variants could contribute as genetic modifiers, 
impacting penetrance and/or expressivity. In this analy-
sis, we have explored only a limited number of clinical 
phenotypes. Further studies with larger numbers of phe-
notypic tags derived from clinical and molecular data will 
increase the power to detect new associations. Finally, 
KCO measurements were missing for a proportion of 
patients which could introduce a selection bias, although 
all the deleterious variants in KDR had phenotypic data 
available in the UK cohort.
Table 4. Comparison of High Impact Likely Loss-of-Func-
tion Variants in KDR in the Human Large-Scale Sequenc-
ing Reference Populations gnomAD and TOPMed With the 






in KDR Individuals Alleles Frequency
gnomAD 
(v2.1)*
20 141 456 282 912 0.000071
gnomAD (v3) 10 71 702 143 404 0.000070
TOPMed 5 62 784 125 568 0.000040
NBR non-PAH 
controls
1 11 889 23 778 0.000042
NBR PAH 
cases
4 1122 2244 0.001783
gnomAD indicates The Genome Aggregation Database; KDR, kinase insert 
domain receptor; LoF, loss of function; NBR, National Institute for Health Re-
search BioResource—Rare Diseases; PAH, pulmonary arterial hypertension; and 
TOPMed, The Trans-Omics for Precision Medicine program.
*KDR constraint metrics: pLI=1; o/e=0.15 [0.09;0.25]; exp(LoF)=73; 
obs(LoF)=11.
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In summary, this study shows that deep phenotyping 
enables patient stratification into subgroups with shared 
pathobiology and with increased power to detect new 
genotype-phenotype associations. We provide statisti-
cal evidence for an association between high impact, 
likely loss-of-function variants in KDR and significantly 
decreased KCO and later disease onset, further sup-
ported by familial segregation.
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